Effects of simvastatin on cardiohemodynamic responses to ischemia–reperfusion in isolated rat hearts
Authors:
- 22 March 2006
- journal article
- research article
- Published by Springer Nature in Heart and Vessels
- Vol. 21 (2) , 116-123
Abstract
Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has long been thought to exert its benefits by reducing cholesterol synthesis, and has been shown to significantly reduce cardiovascular events and mortality in patients with or without coronary artery disease. However, it is still unknown whether acute administration of simvastatin beneficially affects the cardiac function prior or during ischemia–reperfusion. The aim of this study is to evaluate the cardioprotective effect of acute simvastatin treatment on isolated rat hearts or isolated ischemia–reperfusion hearts. Hearts were isolated from male Sprague–Dawley rats and attached to a Langendorff apparatus. The isolated hearts with or without ischemia (15 min) and reperfusion (60 min) were perfused with different concentrations of simvastatin. The parameters of cardiac function (such as left ventricular developed pressure [LVDP], +dp/dt max, and −dp/dt max), heart rate, and coronary flow were recorded. Simvastatin (3–30 µmol/l) significantly increased LVDP, +dp/dt max, and −dp/dt max in isolated rat hearts perfused for 60 min. Heart rate was depressed by 30 µmol/l simvastatin and the coronary flow was increased by 10 and 30 µmol/l simvastatin. At a concentration of 100 µmol/l simvastatin, worsening of heart function and subsequent cardiac arrest occurred. Administration of simvastatin (3–30 µmol/l) significantly preserved cardiac function detected by LVDP, +dp/dt max, and −dp/dt max in the isolated ischemia/reperfused (15/60 min) rat hearts. Simvastatin also significantly decreased heart rate at 30 µmol/l, and increased coronary flow at 10 and 30 µmol/l in these rat hearts. However, the protective effect of simvastatin reverted to increased damage at 100 µmol/l. Only 3 µmol/l simvastatin pretreatment before 15/60 min ischemia–reperfusion altered LVDP, +dp/dt max, and −dp/dt max. Both heart rate and coronary flow were unaltered after simvastatin pretreatment. Since simvastatin at a concentration lower than 100 µmol/l exerted beneficial effects on cardiac function in isolated perfused rat hearts, it could be applied just after myocardial ischemia and reperfusion.Keywords
This publication has 41 references indexed in Scilit:
- Preservation of NO production by statins in the treatment of heart failureCardiovascular Research, 2003
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen SpeciesHypertension, 2001
- Simvastatin and Ca2+ Signaling in Endothelial Cells: Involvement of Rho ProteinBiochemical and Biophysical Research Communications, 2001
- Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effectLife Sciences, 2000
- Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 1997
- Simvastatin Releases Ca2+ from a Thapsigargin-Sensitive Pool and Inhibits InsP3-Dependent Ca2+ Mobilization in Vascular Smooth Muscle CellsJournal of Cardiovascular Pharmacology, 1996
- Cytosolic Ca2+ Increase and Cell Damage in L6 Rat Myoblasts by HMG-CoA Reductase InhibitorsBiochemical and Biophysical Research Communications, 1994
- Simvastatin‐sodium delays cell death of anoxic cardiomyocytes by inhibition of the Na+/Ca2+ exchangerFEBS Letters, 1994
- Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarctionThe American Journal of Cardiology, 1993